{"result": "(\"entity\"<|>THOMSON14<|>ORGANIZATION<|>Thomson14 is referenced as a source for guidelines on the administration of medications through enteral feeding tubes.)\n##\n(\"entity\"<|>SONDA ENTERAL<|>EVENT<|>The enteral feeding tube is a medical device used for delivering nutrition directly to the stomach or duodenum.)\n##\n(\"entity\"<|>FENITOÍNA<|>PERSON<|>Fenitoína is a medication that requires careful monitoring when administered through enteral feeding due to its narrow therapeutic range.)\n##\n(\"entity\"<|>DICUMARÍNICOS<|>PERSON<|>Dicumarínicos are anticoagulant medications that necessitate precautions during enteral feeding administration.)\n##\n(\"entity\"<|>SUCRALFATO<|>PERSON<|>Sucralfate is a medication that should be administered with caution when using enteral feeding tubes.)\n##\n(\"relationship\"<|>THOMSON14<|>SONDA ENTERAL<|>Thomson14 provides guidelines for the proper use of enteral feeding tubes in medication administration<|>8)\n##\n(\"relationship\"<|>FENITOÍNA<|>SONDA ENTERAL<|>Fenitoína requires specific precautions when administered through enteral feeding tubes due to its narrow therapeutic range<|>7)\n##\n(\"relationship\"<|>DICUMARÍNICOS<|>SONDA ENTERAL<|>Dicumarínicos necessitate careful administration protocols when using enteral feeding tubes<|>7)\n##\n(\"relationship\"<|>SUCRALFATO<|>SONDA ENTERAL<|>Sucralfate should be administered with caution through enteral feeding tubes to avoid interactions<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: llega al pH alcalino del duodeno, como el omeprazol. No se deben triturar y disolver en agua, ya que se inactivaría en el estómago. Por otro lado, los gránulos pueden obstruir la sonda. Las cápsulas pueden abrirse, mezclar los gránulos sin triturar con 20 ml de zumo ácido de frutas y administrar por la sonda²⁰.\n- Cápsulas gelatinosas que contienen líquidos. Si las características del fármaco lo permiten, se debe extraer el contenido de la cápsula con una\n---\n714      BLOQUE: DIETAS EN SITUACIONES ESPECIALES\n\n| Tabla 6. Recomendaciones para la administración de medicamentos por sonda enteral. |\n|----------------------------------------------------------------------------------------|\n| · Averiguar la localización del extremo distal de la sonda (gástrica o duodenal). |\n| · Consultar la tabla de especialidades farmacéuticas. Utilizar preferentemente |\n|   las formas farmacéuticas líquidas (soluciones o suspensiones), siguiendo las |\n|   recomendaciones especificadas. Será necesario diluirlas previamente con al menos |\n|   60-90 ml de agua si hay elevada osmolaridad, viscosidad o alto contenido en sorbitol. |\n|   En ocasiones será necesario valorar la elaboración de formulaciones extemporáneas |\n|   o sustituir el principio activo por otro. |\n| · Evitar el uso de medicamentos (jarabes, soluciones, suspensiones) con pH extremos |\n|   (<4 y >10). |\n| · Seguir las recomendaciones en cuanto a modo de administración respecto a la NE |\n|   para evitar interacciones fármaco-nutrición. Con algunos medicamentos es necesario |\n|   interrumpir la dieta antes y después de la administración del medicamento. |\n| · Lavar la sonda con 15-30 ml de agua antes y después de la administración de cada |\n|   fármaco, para evitar incompatibilidades, prevenir la obstrucción de la sonda |\n|   y asegurar que todo el fármaco es administrado. |\n| · Cuando hay que administrar más de un fármaco al mismo paciente, administrar |\n|   cada medicación de forma separada. En el caso de formas farmacéuticas líquidas se |\n|   recomienda administrar primero las formulaciones de menor viscosidad |\n|   y a continuación las de mayor viscosidad. |\n| · No añadir medicación a la bolsa de nutrición enteral. |\n| · Lavar la sonda cada 4 horas con 15-30 ml agua. |\n| · Registrar la cantidad de agua empleada en el proceso, especialmente si el paciente |\n|   es polimedicado o si requiere restricción de fluidos. |\n| · Si la NE es administrada de forma continua y es necesario interrumpir 1-2 horas la |\n|   infusión para administrar algún medicamento, se debe recalcular el ritmo de infusión |\n|   o valorar el empleo de formulaciones con mayor densidad calórica para |\n|   que el aporte nutricional alcanzado sea el óptimo para el paciente. |\n\nModificado de Thomson14.\n\naguja fina. Hay que tener en cuenta que con fre-\ncuencia resulta difícil extraer todo el líquido, por\nlo que la dosis administrada puede ser menor. Si\nes posible, es preferible buscar otra alternativa te-\nrapéutica.\n\nComo norma, no se deben añadir nunca medica-\nmentos a los preparados de nutrición enteral y se\ndebe evitar la administración conjunta de ambos. Si la\nnutrición se administra en perfusión continua, se pue-\nde hacer coincidir la administración de los fármacos\ncon el cambio de frasco, o bien interrumpir el aporte\nde nutrientes (aproximadamente 30 minutos) y lavar\nla sonda antes y después de administrar el fármaco.\nEn caso de que la nutrición se administre en bolos, el\nmedicamento se deberá administrar 1 hora antes o\n2 horas después de cada toma. En el caso de algunos\nmedicamentos, como la fenitoína, dicumarínicos, su-\ncralfato y otros fármacos con estrecho margen tera-\npéutico, las precauciones deben ser mayores. Se reco-\nmienda monitorizar frecuentemente el efecto\nterapéutico o los niveles plasmáticos del fármaco y\nsuspender la infusión de la dieta enteral entre 1-2 ho-\nras. Si se administra más de un fármaco, no deben\n\nmezclarse y es necesario lavar la sonda con al menos\n10 ml después de cada administración12.\n\nLas propiedades físico-químicas del preparado (pH,\nviscosidad, osmolalidad, presencia de determinados\ncomponentes, como el sorbitol) deben ser cuidadosa-\nmente valoradas cuando se va a administrar a través de\nla sonda. Las formas farmacéuticas cuya osm\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}